reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-01 and is reviewed periodically as new material appears.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Severe Phenotype: symptoms appear soon after birth and include hypoglycemia, hepatomegaly, brain dysfunction (encephalopathy) and often cardiomyopathy Intermediate Phenotype: characterized by hypoketotic hypoglycemia and is triggered by infection or fasting during infancy Mild (Late-Onset) Phenotype: presents as muscle weakness (myopathy) and nerve disease (neuropathy) Long-Term Complications: can include peripheral neuropathy and eye damage (retinopathy) Treatments
==== Withdrawn ==== Josh Cortez, former advisor to U.S. representative Monica De La Cruz (ran in the 35th district) Mayra Flores, former U.S. representative from the 34th district (2022–2023) (ran in the 34th district) Jay Furman, physician and nominee for this district in 2024 (ran in the 35th district)
=== Artistic === Blood is one of the body fluids that has been used in art. In particular, the performances of Viennese Actionist Hermann Nitsch, Istvan Kantor, Franko B, Lennie Lee, Ron Athey, Yang Zhichao, Lucas Abela and Kira O'Reilly, along with the photography of Andres Serrano, have incorporated blood as a prominent visual element. Marc Quinn has made sculptures using frozen blood, including a cast of his own head made using his own blood.
== Mechanism of action == In biochemical studies of mitochondria, the effect of atractyloside on the ADP/ATP transport was recognized even before the actual transporter was identified. ATR or CATR bind to the ADP/ATP translocase, which is located on the inner mitochondrial membrane. ATR binds competitively to the translocase competitive up to a concentration of 5 mmol while CATR binds in a non-competitive manner. As a result, the exchange of ADP and ATP is no longer carried out and the cell dies due to lack of energy. The chemical structure and charge distribution of atractyloside is similar to that of ADP: the sulfate groups correspond to the phosphate groups, the glucose part corresponds to the ribose part, and the hydrophobic atractyligenine residue corresponds to the hydrophobic purine residue of ADP. The carboxyl group on the C4 atom of the atractyligenin is important for toxicity. If this is reduced to a hydroxyl group (atractylitriol), the substance becomes non-toxic. Modification of any of the sulfate groups renders the compound non-toxic. On the other hand, the free hydroxy group on the C6 atom of the glucose moiety can be modified without loss of compound potency.
The Paleolithic overlaps with the Pleistocene epoch of geologic time. Both ended 12,000 years ago although the Pleistocene started 2.6 million years ago, 700,000 years after the Paleolithic's start. This epoch experienced important geographic and climatic changes that affected human societies. During the preceding Pliocene, continents had continued to drift from possibly as far as 250 km (160 mi) from their present locations to positions only 70 km (43 mi) from their current location. South America became linked to North America through the Isthmus of Panama, bringing a nearly complete end to South America's distinctive marsupial fauna. The formation of the isthmus had major consequences on global temperatures, because warm equatorial ocean currents were cut off, and the cold Arctic and Antarctic waters lowered temperatures in the now-isolated Atlantic Ocean. Most of Central America formed during the Pliocene to connect the continents of North and South America, allowing fauna from these continents to leave their native habitats and colonize new areas. Africa's collision with Asia created the Mediterranean, cutting off the remnants of the Tethys Ocean. During the Pleistocene, the continents were essentially at their modern positions; the tectonic plates on which they sit have probably moved at most 100 km (62 mi) from each other since the beginning of the period. Climates during the Pliocene became cooler and drier, and seasonal, similar to modern climates. Ice sheets grew on Antarctica.
Sources: en.wikipedia.org
== Detection and classification == Detection of drugs and pharmaceuticals in biological samples is usually done by an initial screening and then a confirmation of the compound(s), which may include a quantitation of the compound(s). The screening and confirmation are usually, but not necessarily, done with different analytical methods. Every analytical method used in forensic toxicology should be carefully tested by performing a validation of the method to ensure correct and indisputable results at all times. The choice of method for testing is highly dependent on what kind of substance one expects to find and the material on which the testing is performed. Customarily, a classification scheme is utilized that places poisons in categories such as: corrosive agents, gases and volatile agents, metallic poisons, non-volatile organic agents, and miscellaneous.
By 1818, the United States Navy had outlined that each sailor was to be given 14 ounces (400 g) of bread per day as part of their daily ration while serving onboard in the form of hardtack. The procurement of these stores was the responsibility of the ship's Purser, and was not strictly outlined by the Board of Navy Commissioners. During the American Civil War (1861–1865), three-by-three-inch (7.6 by 7.6 cm) hardtack was shipped from Union and Confederate storehouses. Civil War soldiers generally found their rations to be unappealing; hardtack's ability to host worms earned it the "worm castles" nickname, and soldiers joked about the poor quality of the hardtack in the satirical song "Hard Tack Come Again No More". The song was sung to the tune of the Stephen Foster song "Hard Times Come Again No More", and featured lyrics describing the hardtack rations as being 'old and very wormy' and causing many 'stomachs sore'. John Billings, a soldier in the 10th Massachusetts Battery, outlines many details on how hardtack was utilized during the war in his book Hard Tack and Coffee.
The major source of nickel exposure is oral consumption, as nickel is essential to plants. Typical background concentrations of nickel do not exceed 20 ng/m3 in air, 100 mg/kg in soil, 10 mg/kg in vegetation, 10 μg/L in freshwater and 1 μg/L in seawater. Environmental concentrations may be increased by human pollution. For example, nickel-plated faucets may contaminate water and soil; mining and smelting may dump nickel into wastewater; nickel–steel alloy cookware and nickel-pigmented dishes may release nickel into food. Air may be polluted by nickel ore refining and fossil fuel combustion. Humans may absorb nickel directly from tobacco smoke and skin contact with jewelry, shampoos, detergents, and coins. A less common form of chronic exposure is through hemodialysis as traces of nickel ions may be absorbed into the plasma from the chelating action of albumin. The average daily exposure is not a threat to human health. Most nickel absorbed by humans is removed by the kidneys and passed out of the body through urine or is eliminated through the gastrointestinal tract without being absorbed. Nickel is not a cumulative poison, but larger doses or chronic inhalation exposure may be toxic, even carcinogenic, and constitute an occupational hazard. Nickel compounds are classified as human carcinogens based on increased respiratory cancer risks observed in epidemiological studies of sulfidic ore refinery workers. This is supported by the positive results of the NTP bioassays with Ni sub-sulfide and Ni oxide in rats and mice.
On 17 July 2007, following a four-year inquiry, the House of Commons Select Committee on Standards and Privileges published its sixth report. The Parliamentary Commissioner for Standards, in an addendum to the report, concluded that there was no evidence that Galloway gained any personal benefit from either the former Iraqi administration, or from the Oil-for-Food Programme, but admitted that some documents had been unavailable to him. However, the Committee concluded, in the main body of the report:
== Usage and Applications == COBRA has been used extensively in many research-based applications such as screening for DNA methylation changes at gene promoters in cancer studies, detecting altered methylation patterns at imprinted genes, and characterizing methylation patterns in the genome during development in mammals. In medicine, COBRA has been used as a tool to help diagnose human disease involving aberrant DNA methylation. Researchers utilized COBRA in conjunction with denaturing high performance liquid chromatography in the diagnosis of the genetic imprinting disorder Russell-Silver syndrome where hypomethylation of the imprinted gene H19 is responsible for the disorder in up to 50% of patients.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.